isolation for those affected by the disease. Lepra sought to move beyond these issues through "evidence-led" policies and practices. Second, Lepra was established as a secular charity, open to all faiths and beliefs, and claiming to favour none above another. In 1929 Dr Robert Cochrane took over from Oldrieve and became BELRA's Medical and General Secretary. In 1931 BELRA was recognised as the 'First leprosy prevention organisation' at the International Leprosy Congress in Manila. In 1935 BELRA launched a Child Adoption Scheme as a method of raising funds for treatment of children who were patients of leprosy hospitals. The child patients were connected with UK sponsors. The royal family would later adopt children through BELRA's Child Adoption Scheme in 1947. In 1945 BELRA became one of the first organisations to methodically trial Dapsone as a treatment for leprosy and record its impact. In 1951 Dr Robert Cochrane became Leprosy Adviser to the UK Ministry of Health. In 1952 The Queen became patron of BELRA. In 1953 BELRA established the first leprosy research centre in Eastern Africa. The site for the East African Leprosy Research Centre was chosen to be within the grounds of the Itesio Leprosarium in Kenya. In 1959 the name of the centre was changed to Alupe. The Centre is now known as The Centre for Infectious and Parasitic Diseases Control Research (CIPDCR) and is one of the 12 centres of the Kenya Medical Research Institute (KEMRI). At the 1957 Annual General Meeting, following the decolonisation process of the British Empire, the Association changed its name to the British Leprosy Relief Association, retaining the abbreviation BELRA. In 1961 BELRA helped to develop Clofazimine (B663), which to this day remains a part of the multi drug therapy used for multi bacillary leprosy. In 1962 A mobile exhibition van started touring the UK, promoting BELRA's work. LEPRA (1964-2013) In 1964 the Association changed its name from BELRA to LEPRA. In 1965 the High Commissioner for Malawi and LEPRA's President, Viscount Boyd, approved an agreement on the Malawi Pilot Leprosy Control project, which subsequently began work. In 1974 LEPRA moved its headquarters from London to Colchester, where its offices are still based today. As a result of research, in 1975 LEPRA became one of the first associations to use multidrug therapy for treating leprosy, to increase effectiveness and minimise drug resistance. In 1976 LEPRA became a full member of the International